Shenqi Fuzheng Injection and Glioma Signaling

The reference study, published in the Journal of Ethnopharmacology, examines how Shenqi Fuzheng injection (SFI) influences glioma biology through an integrated computational and experimental strategy. Rather than treating SFI as a single-target drug, the investigators used network pharmacology to map its potential multi-component, multi-target activity and then tested the resulting hypothesis in glioma cell and mouse models. The study is available as an open-access report through the reference publication.

Study Background and Research Question

Gliomas are invasive brain tumors characterized by sustained proliferation, cellular migration, and difficult therapeutic management. Shenqi Fuzheng injection is a clinical adjunct used alongside cancer chemotherapy, but its molecular basis in glioma remains incompletely defined. The formulation is derived primarily from Codonopsis pilosula and Astragalus membranaceus, two medicinal plants with chemically complex profiles that include flavonoids, saponins, polysaccharides, and other constituents.

The central research question was whether SFI can suppress glioma progression and, if so, which interconnected signaling pathways could explain its effects. The authors focused on proliferation and migration because these phenotypes are directly relevant to glioma expansion and invasion. Their design also asked whether computationally predicted targets could be connected to measurable changes in cell-cycle behavior, epithelial–mesenchymal transition (EMT)-associated markers, and tumor development in vivo.

Key Innovation from the Reference Study

The main innovation is the transition from a broad network-pharmacology prediction to a focused experimental model of SFI action. The analysis identified 110 SFI-associated targets, 26 major active components, 3,343 glioma-related targets, and 79 targets shared by SFI and glioma. These overlapping targets were used to prioritize biological processes and signaling pathways rather than assuming that one compound or one receptor accounts for the activity of the injection.

SRC/PI3K/AKT signaling emerged as a central pathway in the computational analysis. This is biologically plausible because SRC-family signaling and PI3K/AKT activity can influence survival, cell-cycle progression, cytoskeletal remodeling, and migratory behavior. Importantly, the authors did not stop at pathway enrichment. They tested whether SFI produced corresponding phenotypic and protein-level changes in glioma models, strengthening the connection between the predicted network and observed biology.

This combination is valuable for research on complex botanical preparations. Network pharmacology provides a way to organize chemical and target diversity, while functional assays determine whether the predicted relationships are reflected in cell behavior. The approach does not prove that every predicted target is engaged, but it offers a structured route for selecting pathways for validation.

Methods and Experimental Design Insights

The study used U87 and T98G human glioma cells for the principal in vitro experiments and GL261 cells for a subcutaneous mouse tumor model. The cellular workflow assessed several levels of the phenotype. CCK-8 and EdU assays measured metabolic activity and DNA synthesis, while plate-cloning experiments evaluated longer-term proliferative capacity. Scratch-wound and Transwell assays were used to examine migration through complementary two-dimensional and membrane-transit formats.

Mechanistic characterization included immunofluorescence, flow cytometry, and Western blotting. Flow cytometry was particularly relevant to the authors’ conclusion that SFI caused S-phase blockage. Western blotting and immunofluorescence were used to examine pathway-associated proteins and EMT-related markers, providing molecular context for the migration results. In vivo, GL261 cells were implanted subcutaneously into C57BL/6 mice. Tumor tissue was evaluated by hematoxylin and eosin staining and immunohistochemistry, allowing the investigators to compare gross tumor development with tissue-level changes.

Protocol Parameters

• Network scope: The reported analysis integrated SFI-associated targets with glioma-related targets and prioritized the shared network for pathway enrichment; the numerical screening results are described in the reference study.
• In vitro models: U87 and T98G cells were used to assess SFI effects on proliferation, DNA synthesis, clonogenic growth, migration, cell-cycle distribution, EMT-associated markers, and pathway-related protein expression.
• Phenotypic assays: CCK-8, EdU, plate cloning, scratch, and Transwell assays were combined rather than relying on a single proliferation or migration endpoint.
• Mechanistic assays: Flow cytometry, immunofluorescence, and Western blotting were used to connect phenotype with cell-cycle and signaling changes.
• In vivo validation: A subcutaneous GL261 tumor model in C57BL/6 mice was assessed using tumor development, HE staining, and immunohistochemistry.
• Replication recommendation: When adapting the workflow, investigators should retrieve exposure concentrations, treatment schedules, animal allocation, and endpoint definitions from the full Methods section rather than infer them from the condensed findings.

Core Findings and Why They Matter

SFI inhibited proliferation in both U87 and T98G cells. The CCK-8, EdU, and colony-formation results collectively indicate reduced growth capacity, while flow-cytometry data support an S-phase block. This distinction matters because a lower metabolic signal alone can reflect cytotoxicity or altered metabolism; agreement with DNA-synthesis, clonogenic, and cell-cycle measurements provides a more informative picture of growth suppression.

The migration experiments showed that SFI reduced glioma cell movement in scratch and Transwell formats. The authors associated this effect with downregulation of EMT-related marker expression. In glioma, EMT terminology should be interpreted carefully because these tumors are not epithelial cancers in the conventional sense. Nevertheless, changes in EMT-associated proteins can still serve as indicators of altered motility and invasive behavior when interpreted alongside functional migration assays.

The mouse experiments extended the findings beyond cultured cells. In the transplanted tumor model, SFI reduced tumor development, and tissue analyses provided histological and immunohistochemical support for an in vivo effect. The study therefore links three levels of evidence: target-network prediction, cellular phenotype, and tumor growth.

The SRC/PI3K/AKT pathway is the study’s principal mechanistic interpretation. Its importance lies less in identifying a completely new signaling axis than in showing how a complex botanical formulation may converge on a pathway that regulates several glioma-relevant phenotypes simultaneously. However, pathway enrichment and expression changes establish involvement more readily than direct causality. Stronger causal evidence would require targeted perturbation, such as pathway inhibition, genetic rescue, or constitutively active signaling experiments.

Comparison with Existing Internal Articles

The internal article Network Pharmacology Reveals SFI's Role in Blocking Glioma Progression provides a concise companion interpretation of the same study, emphasizing the relationship between SFI, glioma progression, and SRC/PI3K/AKT signaling. Its value is contextual and explanatory rather than evidentiary: the DOI-linked publication remains the primary source for the experimental design, numerical target analysis, and reported results. For researchers, the two resources are best read together, with the internal summary used for orientation and the original article used for methodological decisions.

Limitations and Transferability

Several limitations affect how broadly the findings can be applied. First, network pharmacology depends on the quality and completeness of compound, target, and disease annotations. The 79 shared targets identify plausible points of convergence, but they do not establish which SFI constituents reach glioma tissue or engage those targets at biologically relevant concentrations.

Second, the experimental work used a limited set of cell lines and a subcutaneous GL261 model. These systems are useful for controlled assessment of proliferation and migration, but they do not fully reproduce the anatomical constraints of the brain, the blood–brain barrier, orthotopic tumor architecture, or the complete glioma microenvironment. Results should therefore be considered preclinical and hypothesis-generating rather than evidence of clinical efficacy.

Third, the reported pathway interpretation would benefit from more direct intervention. Changes in SRC/PI3K/AKT-associated proteins can accompany growth inhibition without being the sole cause of it. Component-resolved studies, pharmacokinetic measurements, target-engagement assays, and genetic or pharmacological rescue experiments would help separate primary pathway effects from downstream consequences of cellular stress.

Why this cross-domain matters, maturity, and limitations

The SFI study can inform tumor angiogenesis research only indirectly. Its principal endpoints were glioma proliferation, migration, cell-cycle distribution, EMT-associated markers, and tumor growth; it did not directly establish changes in vessel density, endothelial signaling, or VEGF receptor activity. Consequently, an anti-angiogenic compound or angiogenesis inhibitor should be treated as a mechanistically distinct comparator rather than as a substitute for SFI or a validation of the SRC/PI3K/AKT conclusion.

This distinction is important when comparing tumor models. Findings from melanoma tumor growth inhibition experiments cannot be transferred automatically to glioma, because tumor lineage, vascular organization, tissue accessibility, and immune context differ. A cross-domain workflow may still be useful for hypothesis generation if vascular endpoints are prespecified and analyzed separately from glioma-cell phenotypes. Its maturity remains exploratory and preclinical, and any interpretation should preserve the difference between direct evidence from the reference study and results obtained with an independent angiogenesis-focused tool.

Research Support Resources

For a separate angiogenesis-focused workflow, researchers can use AAL-993 (SKU C3730), a VEGF receptor inhibitor reported to target VEGFR-1, VEGFR-2, and VEGFR-3. It may serve as a pathway probe or comparator in tumor angiogenesis research, but its use should not be interpreted as a replication of SFI’s glioma mechanism; it is intended for scientific research rather than diagnostic or medical use.